Stock 688192 DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Equities

688192

CNE1000055W8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
44.39 CNY +3.26% Intraday chart for Dizal (Jiangsu) Pharmaceutical Co., Ltd. +25.40% -7.23%
Apr. 24 Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer CI
Apr. 07 U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 14,959 16,030 18,451 18,451 -
Enterprise Value (EV) 1 14,959 16,030 19,530 18,451 18,451
P/E ratio -19.9 x -21.6 x -17.4 x -28.5 x -35.9 x
Yield - - - - -
Capitalization / Revenue 1,454 x - 214 x 37.7 x 17.5 x
EV / Revenue 1,454 x - 214 x 37.7 x 17.5 x
EV / EBITDA - -23.2 x -20.9 x -31.3 x -42.6 x
EV / FCF - -23.7 x -17.1 x -23.6 x -39.6 x
FCF Yield - -4.22% -5.85% -4.24% -2.53%
Price to Book 6.07 x 9.11 x 23.5 x 2,220 x -27.8 x
Nbr of stocks (in thousands) 404,183 407,160 415,653 415,653 -
Reference price 2 37.01 39.37 44.39 44.39 44.39
Announcement Date 2/25/22 2/27/23 2/23/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 - 10.29 - 91.29 490 1,056
EBITDA 1 - - -692.4 -883.5 -590 -433
EBIT 1 - -669.9 -735.7 -1,123 -649 -509
Operating Margin - -6,512.85% - -1,230.49% -132.45% -48.2%
Earnings before Tax (EBT) 1 - -669.9 -735.7 -989.3 -649 -509
Net income 1 -586.6 -669.9 -736 -1,123 -649 -509
Net margin - -6,512.85% - -1,230.6% -132.45% -48.2%
EPS 2 -1.630 -1.860 -1.820 -2.750 -1.560 -1.235
Free Cash Flow 1 - - -677.2 -1,079 -781.9 -466.5
FCF margin - - - -999% -159.57% -44.18%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 11/22/21 2/25/22 2/27/23 2/23/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - -677 -1,079 -782 -467
ROE (net income / shareholders' equity) - -37.8% -34.9% -86.7% -198% -102%
ROA (Net income/ Total Assets) - - -30.5% -62.8% -62.8% -38.3%
Assets 1 - - 2,414 1,789 1,033 1,329
Book Value Per Share 2 - 6.090 4.320 2.040 0.0200 -1.600
Cash Flow per Share 2 - -1.370 -1.480 -2.520 -1.910 -1.060
Capex 1 - - 73.8 100 82 162
Capex / Sales - - - 92.59% 16.73% 15.29%
Announcement Date 11/22/21 2/25/22 2/27/23 2/23/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
44.39 CNY
Average target price
52.16 CNY
Spread / Average Target
+17.49%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. Stock Dizal (Jiangsu) Pharmaceutical Co., Ltd.
-7.23% 2.55B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688192 Stock
  4. Financials Dizal (Jiangsu) Pharmaceutical Co., Ltd.